"label","description","instanceType","id","name","rationale","uuid:ID"
"","The main design for the study","StudyDesign","StudyDesign_1","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","004555ba-7200-4e09-bfef-5d768fd6a9c8"
